Biopharmaceutical firm Ocugen has outlined a definitive regulatory strategy for its leading gene therapy candidates, targeting three separate Biologics License Application (BLA) submissions between 2026 and 2028. This accelerated clinical pathway is now supported by strengthened financial resources.
Financial Runway and Divergent Analyst Views
The company’s liquidity position, bolstered by a $15 million warrant exercise completed in March, is projected to fund operations through the first quarter of 2027. This capital is deemed sufficient to complete the BLA process for its lead candidate and initiate a pivotal Phase 3 trial.
Market analysts hold mixed views on the financial outlook. HC Wainwright analysts slightly adjusted their first-quarter 2026 earnings per share (EPS) estimate to a loss of $0.05 and reaffirmed a $10.00 price target with a “Buy” rating. In contrast, Noble Financial revised its third-quarter 2026 expectation to a loss of $0.07 per share. The consensus estimate for the full year 2026 stands at a loss of $0.20 per share.
A separate regulatory filing from asset manager Vanguard garnered attention, showing a reported 0% stake. This reflects an internal restructuring where individual Vanguard subsidiaries will now report holdings separately, not an actual divestment of Ocugen shares.
Should investors sell immediately? Or is it worth buying Ocugen?
The stock, trading notably above its 200-day moving average but approximately 25% below its 52-week high of €2.17, appears to reflect a market that has priced in potential but awaits execution. The next concrete milestone is the initiation of the rolling BLA submission for OCU400 in the third quarter of 2026.
A Detailed Look at the Clinical Roadmap
The updated corporate strategy centers on three ophthalmology programs, each with a defined regulatory path:
- OCU400 for Retinitis Pigmentosa: The company plans to commence a rolling BLA submission starting in Q3 2026.
- OCU410ST for Stargardt Disease: Topline data from a Phase 2/3 trial is anticipated in Q2 2027, to be followed by a formal BLA application.
- OCU410 for Geographic Atrophy: A global Phase 3 study for this candidate is also scheduled to begin in Q3 2026.
For OCU410, 12-month data from the Phase 2 ArMaDa study provided preliminary guidance. The mid-dose cohort demonstrated a 31% reduction in the growth of macular lesions—a result that is expected to inform the design of the upcoming Phase 3 trial.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from March 28 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 28.
Ocugen: Buy or sell? Read more here...
